CAMBRIDGE, Mass., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, announces that results from the single agent dose-escalation portion of the ongoing Phase 1 study of AG-270 ...

Agios Pharmaceuticals ( AGIO ) announced that it had obtained positive results in a phase 3 study treating patients with bile duct cancer. Specifically, these are patients who have the IDH1 mutation. The company obtained these positive results using its drug Tibsovo. The thing is that Tibs...

– TIBSOVO ® Reduced the Risk of Disease Progression or Death by 63% (HR=0.37, p<0.001); Median PFS for Patients Randomized to TIBSOVO ® was 2.7 months Compared to 1.4 Months with Placebo – – TIBSOVO ® Patients Had 6-month PFS Rate of 32% and 1...